Shakeel Modak

List of Publications by Year
in descending order

56 papers	2,703 citations	218662 26 h-index	189881 50 g-index
57 all docs	57 docs citations	57 times ranked	4253 citing authors

#	Article	IF	Citations
1	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. Journal of Nuclear Cardiology, 2022, 29, 3179-3188.	2.1	7
2	Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. Journal of Clinical Oncology, 2021, 39, 215-226.	1.6	60
3	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
4	Differential Impact of ALK Mutations in Neuroblastoma. JCO Precision Oncology, 2021, 5, 492-500.	3.0	6
5	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	3.4	14
6	Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCNâ€amplified neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e29265.	1.5	7
7	Mandibular metastases in neuroblastoma: Outcomes and dental sequelae. Pediatric Blood and Cancer, 2021, 68, e28918.	1.5	4
8	Phase I Trial of Oral Yeast-Derived Î²-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 2021, 13, 6265.	3.7	6
9	A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor. Journal of Pediatric Surgery, 2020, 55, 376-380.	1.6	9
10	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
11	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. Journal of Clinical Oncology, 2020, 38, 4283-4291.	1.6	40
12	Nivolumab in paediatric cancer: children are not little adults. Lancet Oncology, The, 2020, 21, 474-476.	10.7	7
13	Reducedâ€dose craniospinal irradiation for central nervous system relapsed neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28364.	1.5	7
14	Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27960.	1.5	5
15	Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 409-414.	0.8	13
16	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. Journal of Pediatric Hematology/Oncology, 2019, 41, e257-e259.	0.6	4
17	Doseâ€escalation is needed for gross disease in highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27009.	1.5	17
18	Treatment and outcome of adultâ€onset neuroblastoma. International Journal of Cancer, 2018, 143, 1249-1258.	5.1	23

#	Article	IF	Citations
19	Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1204-1209.	0.8	19
20	Humanized 3F8 Anti-G_{D2}Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma. JAMA Oncology, 2018, 4, 1729.	7.1	86
21	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology, 2018, 7, e1461305.	4.6	49
22	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
23	Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric Blood and Cancer, 2017, 64, e26448.	1.5	44
24	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441.	7.0	134
25	Failure of MIBG scan to detect metastases in SDHBâ€mutated pediatric metastatic pheochromocytoma. Pediatric Blood and Cancer, 2017, 64, e26549.	1.5	10
26	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26409.	1.5	66
27	Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology, 2017, 6, e1358331.	4.6	25
28	Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy, 2017, 17, 889-904.	2.4	128
29	Acute myeloid leukemia therapy elicits durable complete response in chemoradioâ€resistant metastatic paraganglioma. Pediatric Blood and Cancer, 2017, 64, e26314.	1.5	2
30	A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: <scp>L</scp>ongâ€term progressionâ€free survival of patients with resistant neuroblastoma. International Journal of Cancer, 2017, 140, 480-484.	5.1	41
31	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	2.5	38
32	MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget, 2017, 8, 95293-95302.	1.8	10
33	Is Extended Sedation Necessary for Young Children Receiving Highâ€Dose ¹³¹Iâ€MIBG Therapy?. Pediatric Blood and Cancer, 2016, 63, 1867-1867.	1.5	1
34	Feasibility of Administering High-Dose¹³¹I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. Pediatric Blood and Cancer, 2016, 63, 801-807.	1.5	17
35	Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 393-400.	0.8	36
36	Management of desmoplastic small round cell tumor. Seminars in Pediatric Surgery, 2016, 25, 299-304.	1.1	62

#	Article	IF	Citations
37	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of Nuclear Medicine, 2016, 57, 231-237.	5.0	17
38	Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. Journal of Pediatric Surgery, 2016, 51, 285-288.	1.6	7
39	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS Genetics, 2016, 12, e1006501.	3.5	98
40	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget, 2016, 7, 4155-4166.	1.8	51
41	Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e381-e383.	0.6	10
42	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. Sarcoma, 2015, 2015, 1-9.	1.3	21
43	Osteochondroma in longâ€term survivors of highâ€risk neuroblastoma. Cancer, 2015, 121, 2090-2096.	4.1	15
44	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_{D2}immunotherapy and isotretinoin: a prospective Phase II study. OncoImmunology, 2015, 4, e1016704.	4.6	52
45	Anti-GD2 antibody 3F8 and barley-derived (1 â†' 3),(1 â†' 4)-Î²-D-glucan. OncoImmunology, 2013, 2, e23402	4.6	30
46	Plerixafor plus granulocyteâ€colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatric Blood and Cancer, 2012, 58, 469-471.	1.5	26
47	Updates in the treatment of neuroblastoma. Clinical Advances in Hematology and Oncology, 2011, 9, 74-6.	0.3	2
48	Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treatment Reviews, 2010, 36, 307-317.	7.7	141
49	Reply to K. Satharasinghe et al. Journal of Clinical Oncology, 2009, 27, e235-e235.	1.6	2
50	Transient sialoadenitis: A complication of ¹³¹Iâ€metaiodobenzylguanidine therapy. Pediatric Blood and Cancer, 2008, 50, 1271-1273.	1.5	36
51	Disialoganglioside Directed Immunotherapy of Neuroblastoma. Cancer Investigation, 2007, 25, 67-77.	1.3	105
52	Rituximab therapy of lymphoma is enhanced by orally administered (1â†'3),(1â†'4)-d-Î²-glucan. Leukemia Research, 2005, 29, 679-683.	0.8	75
53	Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 534-546.	1.0	35
54	Antibody-based targeted radiation to pediatric tumors. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 157S-63S.	5.0	8

#	Article	IF	Citations
55	Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors. Journal of Clinical Oncology, 2004, 22, 1934-1943.	1.6	123
56	Disialoganglioside G_{D2} and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor. Medical and Pediatric Oncology, 2002, 39, 547-551.	1.0	54